Saturday, October 3, 2026

Traditional VCs Reclaim 80% of Major Deals as Tiger Global, SoftBank Cut Activity 95% Globally

Silicon Valley venture firms now lead 8 of 10 funding rounds above $50 million worldwide in 2025, reversing the dominance of mega-investors Tiger Global and SoftBank, which slashed deal activity over 95%. Global fundraising at this tier fell 50% to 1,440 deals from 2,880 in 2021, while valuations recovered on stronger fundamentals.

ViaNews Editorial Team

February 27, 2026

Source Trace Score12 source documents12 with a live linkVerifiability: High
Traditional VCs Reclaim 80% of Major Deals as Tiger Global, SoftBank Cut Activity 95% Globally
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Traditional venture capital firms control 8 of the top 10 positions for leading funding rounds of $50 million or more globally in 2025, marking a sharp reversal from 2021 when Tiger Global Management and SoftBank Vision Fund dominated startup financing across markets. The two mega-investors have reduced their deal count by more than 95% since the peak three years ago.

Worldwide, companies raising $50 million or more dropped roughly 50% to 1,440 deals in 2025 from approximately 2,880 in 2021. Valuations recovered alongside this contraction across North America, Europe, and Asia, suggesting stronger business fundamentals now support pricing despite lower deal volume.

The retreat of crossover funds and corporate venture arms created openings for traditional VC partnerships to reassert control over AI-wave investments. Private equity firms, which overindexed in private companies globally during 2021's boom, scaled back significantly as exit conditions tightened in major markets.

Limited partners now expect fund durations extending to 18 years as deployment timelines stretch and exit windows remain uncertain worldwide. Portfolio companies require more runway to reach liquidity events, with IPO markets from New York to London selective and M&A activity concentrated in strategic acquisitions rather than financial exits.

The discipline imposed by reduced capital availability contrasts sharply with 2021's rapid-fire dealmaking. Firms deploying hundreds of millions monthly three years ago across multiple geographies now conduct fewer than a dozen large rounds annually, prioritizing due diligence over speed regardless of region.

Portfolio construction reflects the new environment's complexity. Makena Capital views its Stripe exposure as a hedge against Visa, anticipating crypto payment rails could disrupt traditional card networks globally. This cross-asset positioning reflects longer hold periods requiring macroeconomic scenario planning across currencies and regulatory regimes.

The central question facing investors worldwide: whether the 2025 cohort of highly valued companies will generate outsized returns comparable to previous venture cycles. Unlike 2021's indiscriminate capital deployment, current pricing reflects competition among specialized investors rather than tourist capital chasing momentum across borders.

The fundraising environment favors companies with demonstrated product-market fit and clear paths to profitability, regardless of geography. Founders face fewer term sheet options but encounter investors with deeper sector knowledge and operational networks spanning continents, potentially improving long-term partnership quality over transactional capital relationships.

Source documents

Via News is a conduit. We point to the source documents behind this report — we don't replace them. Trace any claim to its source and decide what to trust. How we source

Source Trace Score12 source documents12 with a live linkVerifiability: High
  1. [1]Press releaseGlobeNewswire· December 3, 2025
    Allison Ames, Susan Brandt, Steven Ekstract, Hallmark, Dolly Parton, and Kevin Smith Join Licensing International Hall of Fame
  2. [2]News articleYahoo Finance· January 19, 2026
    Andreessen Horowitz Makes a $3 Billion Bet Against the AI Bubble
  3. [3]News articleCrunchbase News
    Crunchbase Data: The AI Boom Has Drastically Changed Who’s Funding The Hottest Companies In 2025 Vs. 2021
  4. [4]News articleYahoo Finance· November 18, 2025
    ‘Our funds are 20 years old’: limited partners confront VCs’ liquidity crisis
  5. [5]News articleYahoo Finance· February 20, 2026
    The OpenAI mafia: 18 startups founded by alumni
  6. [6]Press releaseGlobeNewswire· November 13, 2025
    Equillium Reports Third Quarter 2025 Financial Results and Provides Operational Update
  7. [7]Earnings callNasdaq· February 25, 2026
    Erie Indemnity (ERIE) Q4 2025 Earnings Transcript
  8. [8]Press releaseGlobeNewswire· February 25, 2026
    Marketing Technology (MarTech) Market Worth USD 3.28 Trillion by 2035 Driven by AI, Agile Marketing, and Privacy-First Personalization
  9. [9]News articleYahoo Finance· February 25, 2026
    Oak-Eagle AcquireCo, Inc. Announces Pricing Terms for the Previously Announced Tender Offers and Consent Solicitations for Any and All of Electronic Arts Inc.'s 1.850% Senior Notes Due 2031 and 2.950% Senior Notes Due 2051
  10. [10]Press releaseGlobeNewswire· February 10, 2026
    OnSpark Launches AI-Powered Partnership Engine Built to Replace Guesswork With Verified Growth Opportunities
  11. [11]Press releaseGlobeNewswire· February 23, 2026
    Recyclable Polyethylene-Based Laminates Market Set Projected to Reach USD 5.92 Billion by 2035 with a 9.0% CAGR
  12. [12]News articleYahoo Finance· February 23, 2026
    Ripple CEO: 90% Chance Crypto Bill Passes By April, But What Do Prediction Markets Say?

In this story · Knowledge Files

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Pharma Pipeline Catalysts and M&A Heat Up as AI-Designed Drugs Enter the Clinic
Late-September 2026 brought a dense run of clinical readouts: Novo Nordisk's CagriSema data at EASD, Lilly's ADtouch results for EBGLYSS, and Merck's tulisokibart Phase 2b result. Lilly's $2.9B Merida Biosciences acquisition and the 2026-11-14 FDA PDUFA date for ivonescimab sit alongside these as the main deal and regulatory events. AI-designed drugs such as rentosertib, and speculative AI-linked trial ventures such as QAIAx, are moving from hype toward clinical validation. Broader AI-sector regulatory and legal friction (Tesla Cybercab probe, xAI Minnesota ruling, OpenAI lawsuits) shows rising scrutiny that could spill into AI-driven healthcare.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Apple Inc.
The observation date (2025-12-27) precedes Q1 2026, making it logically impossible to have actual Q1 2026 cash data at that point. Q1 2026 would not end until March 31, 2026. Additionally, the magnitude of the difference ($45.3B vs $132.42) is implausibly large even as a normal quarterly change for Apple. While different fiscal periods can show different values, the timing relationship here suggests a data integrity issue rather than legitimate period-over-period variation.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,985
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,985 facts checked against source5,329 source documents archived
Query this data → isubstrate.com